Skip to content

Programmed Intermittent Epidural Bolus Versus Continuous Infusion in Labour Analgesia

Programmed Intermittent Epidural Bolus Versus Continuous Infusion When Added to Patient-controlled Epidural Analgesia on Bupivacaine Consumption in Labour Analgesia: a Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03730753
Enrollment
200
Registered
2018-11-05
Start date
2019-06-01
Completion date
2025-06-30
Last updated
2023-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Labor Pain

Brief summary

This study aims to establish if programmed intermittent epidural bolus combined to patient controlled analgesia in labour analgesia will lower the hourly bupivacaine consumption when compared to continuous infusion combined with patient controlled analgesia. The investigators' hypothesis is that the use of programmed intermittent epidural bolus will lower the hourly bupivacaine consumption.

Detailed description

Patients are randomised to receive either a programmed bolus of 6ml each 45 minutes or a continuous infusion of 8ml/h. In each group, they have the possibility to add a PCEA bolus of 6ml every 20min as needed.

Interventions

Programmed intermittent epidural bolus added to patient controlled epidural analgesia

Continuous infusion added to patient controlled epidural analgesia

Sponsors

Université de Sherbrooke
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Pregnant nulliparous or multiparous woman in labour * Age ≥18 years * Obtained consent for epidural analgesia * ASA classification I-II-III * Early labour (cervical dilation ≤6cm)

Exclusion criteria

* Pregnancy-related comorbidities (preeclampsia, eclampsia, gestational diabetes, large for gestational age fetus) * Prematurity (\<36 weeks of gestation) * Multiple gestation * Fentanyl allergy or hypersensitivity * Patient unable to understand the PCEA * Fetal breech position * Maternal cardiac pathology and contraindication to Valsalva manoeuvre * Patient with a pain visual analog scale (VAS) not ≤1/10 20 minutes after the anesthesiologist's initial bolus * Intrathecal catheter or intravascular catheter * Accidental dural puncture * Patient refusal * Patient with a history of chronic pain (pain lasting more than 3 months) or fibromyalgia

Design outcomes

Primary

MeasureTime frameDescription
Dose of bupivacaine in milligrams per hour1 dayTotal dose of bupivacaine in milligrams divided by the total duration of the epidural in hours

Secondary

MeasureTime frameDescription
Anesthesiologist manual bolus1 dayTotal boluses by the anesthesiologist
PCEA boluses received1 dayPCEA boluses received
PCEA boluses requested1 dayPCEA boluses requested
Time lapse before the first PCEA request after the epidural connection1 dayTime lapse before the first PCEA request after the epidural connection
First stage1 dayDuration of the first stage of labour
Evaluation of pain1 dayHourly pain measurement by visual analog scale, 0/10 being no pain and 10/10 being the worst pain imaginable
Assisted vaginal delivery1 dayNumber of assisted vaginal delivery (vacuum, forceps)
Cesarean section1 dayNumber of unplanned cesarean section
Motor blockade1 dayNumber of patients with a Bromage score ≥1
Patient satisfaction1 daySatisfaction of the analgesia provided by the epidural on a visual analog scale of 0-100, 0/100 being no satisfaction at all and 100/100 being entirely satisfied
Second stage1 dayDuration of the second stage of labour

Countries

Canada

Contacts

Primary ContactIsabelle Caron, Dr.
isabelle.caron4@usherbrooke.ca+1 819 346-1110
Backup ContactGeneviève Rivard, Dr.
genevieve.rivard2@usherbrooke.ca+1 819 346-1110

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026